Vir Biotechnology Licenses Technology to Gilead for Up to $1.9 Billion
Vir Biotechnology (VIR) announced a licensing agreement with Gilead Sciences (GILD), valued at up to nearly $1.9 billion, aimed at discovering and developing cancer drugs using Vir's PRO-XTEN masking technology platform. The deal led to an almost 10% rise in Vir’s stock price during premarket trading on Wednesday. The partnership allows Gilead access to a novel drug development approach that could enhance the therapeutic potential of existing treatments, particularly for oncology applications. This collaboration highlights growing interest from major pharmaceutical companies in innovative biotech platforms and may accelerate clinical advancements in cancer care through enhanced molecule stability and delivery methods.
Topics: Biotechnology Cancer Drugs Pharmaceuticals